SpineGuard, an innovative company that deploys its DSG® (Dynamic Surgical Guidance) local conductivity sensing technology to secure and streamline the placement of bone implants, announces its commercial partner Omnia Medical launched their codeveloped product PsiFGuard in the USA during the NANS (North American Neuromodulation Society) convention in Orlando, Florida (USA) from January 30th to February 1st, 2025.
Related: Ibex Medical Analytics receives first FDA 510(k) clearance for Ibex Prostate Detect
Stéphane Bette, Deputy CEO and co-founder of SpineGuard, stated: “We are particularly excited to collaborate with Omnia Medical to launch PsiFGuard in the market with the support of the clinical experts from our team who recently joined Omnia. PsiFGuard is part of an innovative solution combining our technologies into an integrated kit matching perfectly the practical needs of healthcare providers offering ambulatory sacro-iliac joint fusion procedures to patients. Omnia Medical is the pioneer company in this area and continues to deliver to physicians an unmatched clinical value proposition thanks to the efficacy of our PsiFGuard device in locating the SI joint. For SpineGuard, this new sacroiliac application of our DSG® technology embedded in a well reimbursed fast-growing procedure represents a game-changing opportunity of fast adoption by the market and significant contribution to the growth of our revenue.”
Troy Schifano, CEO and Co-Founder of Omnia Medical, added: “The NANS convention served to strengthen our conviction that PsiFGuard is an enabling technology needed by the market to bolster physicians’ confidence that they are properly placing the implant in the sacroiliac joint for maximum efficacy. The convention was well attended, and many physicians are eager to be trained on our procedure with this technology. When coupled with the results and feedback from the procedures we did prior to NANS, we expect solid growth through the year and beyond from a rapidly expanding base of physicians.”
